2019
Aggressive Subsets of Metastatic Triple Negative Breast Cancer
Singh J, Asad S, Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, Winer EP, Lin NU, Partridge AH, Overmoyer B, Stover DG. Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clinical Breast Cancer 2019, 20: e20-e26. PMID: 31631016, DOI: 10.1016/j.clbc.2019.06.012.Peer-Reviewed Original ResearchConceptsMetastatic triple-negative breast cancerInflammatory breast cancerTriple-negative breast cancerWorse overall survivalYounger patientsOverall survivalBreast cancerIBC groupMetastatic breast cancer subtypesYounger groupFrequent lung metastasisMedian overall survivalSite of metastasisSingle-institution cohortNegative breast cancerBreast cancer subtypesClinicopathologic characteristicsMetastatic diagnosisMetastatic sitesWorse prognosisLung metastasesPoor prognosisSurvival outcomesPrimary diagnosisAggressive subset
2016
The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis
Stover DG, Coloff JL, Barry WT, Brugge JS, Winer EP, Selfors LM. The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis. Clinical Cancer Research 2016, 22: 6039-6050. PMID: 27330058, PMCID: PMC5161615, DOI: 10.1158/1078-0432.ccr-16-0471.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNeoadjuvant chemotherapyPathologic complete responseBreast cancerGene expression signaturesComplete responseExpression signaturesPrimary breast cancer biopsiesImmune activation signatureBreast cancer biopsiesRole of proliferationClinicopathologic characteristicsSignature scoreImmune activityCancer biopsiesPAM50 subtypesBreast tumorsProliferation differencesCancerActivation signatureNeoadjuvant chemosensitivityChemosensitivityTumorsDNA damageScores
2014
Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. Journal Of The National Comprehensive Cancer Network 2014, 12: 71-80. PMID: 24453294, DOI: 10.6004/jnccn.2014.0008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm MetastasisNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTriple Negative Breast NeoplasmsConceptsMetastatic breast cancerDuration of chemotherapyLines of therapyBreast cancerTumor subtypesDana-Farber Cancer InstituteSixth-line therapyMedian overall survivalBenefit of chemotherapyResult of progressionWarrants further studyChemotherapy linesChemotherapy regimenProlonged therapyMBC diagnosisMedian durationOverall survivalClinicopathologic characteristicsConsecutive patientsMedian ageClinical benefitMedical recordsChemotherapyCancer InstitutePatients